BioCentury
ARTICLE | Clinical News

Myriad Genetics reports data for lung cancer test

September 26, 2013 1:11 AM UTC

Myriad Genetics Inc. (NASDAQ:MYGN) reported data from a validation study analyzing tumor samples from 841 patients with early stage, resectable lung adenocarcinoma showing that its myPlan Lung Cancer ...